Get notified of page updates

Search Results: Treatment + Pancreatic Cancer (3 results)

New Search
PRINTER FRIENDLY PAGE 1 through 3 of 3

Treatment
Phase 1b/2 treatment study for newly diagnosed pancreatic cancer that can be removed with surgery and who have not yet received treatment

Comparing Two Vaccine Treatments With Immunotherapy for Pancreatic Cancer Before and After Surgery

This study is testing two different vaccine-based treatment approaches combined with immunotherapy for people with pancreatic cancer that can be removed with surgery

Clinicaltrials.gov identifier: NCT06782932

Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation

Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors

This study is testing a new treatment that combines a KRAS-targeted cancer vaccine (ELI-002) with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancers with a KRAS tumor mutation and a marker known as mismatch repair proficiency (pMMR or MMR-p).

Clinicaltrials.gov identifier: NCT06411691

Treatment
Phase 2 treatment study for advanced pancreatic and lung cancer

Testing a Combination of Immunotherapy and a Vaccine in People With Advanced Pancreatic or Lung Cancer

This is a Phase 2 treatment trial enrolling adults with advanced pancreatic cancer or advanced non-small cell lung cancer that has continued to grow despite standard immunotherapy.

Clinicaltrials.gov identifier: NCT06015724
Additional Results on Clinicaltrials.gov Treatment + Pancreatic Cancer + vaccine
5 results
Clinical Trial Official Title
NCT04157127 Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT06202066 Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
NCT05013216 Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT06782932 Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
NCT02600949 Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Sponsored By